Veracyte, Inc. (VCYT)
OvervaluedFundamental
71
Price
$47.93
Market Cap
$3.72B
Part 1 · What the company is worth
Overview
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$562M
Trailing 12 months (through 6/30/2026)
Net Income
$114M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$127M
Total Equity
$1.31B
Total Liabilities
$96M
Current Ratio
9.16
Interest Coverage
-
Debt/EBITDA
0.51
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$36.99
Current Price
$47.93
Margin of Safety
-29.6%
Fair Value Range
$24.04 - $49.94
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
34.24
ROE
5.1%
P/B Ratio
2.78
P/FCF
23.21
Gross Margin
71.7%
ROIC
5.9%
Profitability Radar
Value Creation (Economic Moat)
ROIC
5.9%
WACC
15.3%
ROIC − WACC
-9.4 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (19)
- EPS shows upward trend
- Price CAGR 18.93%
- ROIC 5.9%
- Gross margin 71.7%
- P/FCF 23.21
- P/B ratio 2.78
- Debt/equity ratio
- Operating margin 18.8%
- Positive free cash flow
- CapEx intensity
- Current ratio
- Debt/EBITDA
- Return on tangible assets
- ROE 8.6%
- Revenue growth 5Y 34.5%
- Earnings surprise, average 90.4%
- Earnings quality (operating cash flow / net income) 1.56
- Net margin trend 20.4% vs 5.5%
- Piotroski F-Score 8/9
Failed (4)
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Share dilution 3.9%
Unavailable (3)
- Dividend payout –
- Interest coverage
- PEG ratio (needs P/E > 0 and growth > 0)
Piotroski F-Score
Strong financial health
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Marc A. Stapley | CEO & Director | 55 |
| Ms. Rebecca Chambers | Executive VP & CFO | 47 |
| Dr. Phillip G. Febbo M.D. | Chief Scientific & Medical Officer | 59 |
| Ms. Annie McGuire | Executive VP, General Counsel & Head of Market Access | 45 |
| Dr. John Leite Ph.D. | Global Chief Commercial Officer | 53 |
| Dr. Keith Gligorich Ph.D. | Senior Vice President of Global Operations | - |
| Mr. Jonathan Wygant | VP & Chief Accounting Officer | 54 |
| Dr. Kevin Richard Haas Ph.D. | Chief Development & Technology Officer | 40 |
| Mr. Steven French | Senior VP & Chief Information Officer | - |
| Ms. Kelly Gura | Director of Investor Relations | - |
Audit Risk
2
Board Risk
2
Compensation Risk
5
Shareholder Rights Risk
4
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-26
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-07-31
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-14
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much VCYT moves, measured on its daily prices.
More volatile than 90% of the tracked stocks (90-day volatility).
- Volatility 30d
- 59.8%
- Volatility 90d
- 67.3%
- Beta vs S&P 500 (1y)
- 1.53Correlation 0.30
- Max drawdown (12m)
- -39.2%
- ATR (14d, % of price)
- 4.86%
Earnings reactions
How VCYT moved around its past quarterly results.
Next earnings release
Nov 4, 2026 · In 11 days · Time not known
EPS estimate: 0.41Revenue estimate: $147M
What usually happens
- Over the last 12 releases the stock moved a median of 11.9% the next day, up or down.
- Next-day moves: up 7, down 5 (out of 12).
- Of the 4 releases that beat estimates, the stock fell the next day after 1.
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | After the close | 0.27 | 0.31 | +16.9% | -18.4% | -22.5% | -22.8% |
| May 5, 2026 | After the close | 0.15 | 0.35 | +133.2% | +18.3% | +24.9% | +20.0% |
| Feb 25, 2026 | After the close | 0.22 | 0.51 | +132.6% | +7.8% | +8.5% | +1.5% |
| Nov 4, 2025 | After the close | 0.13 | 0.24 | +79.0% | +10.7% | +27.5% | +18.1% |
| Aug 6, 2025 | After the close | n/a | n/a | n/a | +8.5% | +15.5% | +28.0% |
| May 7, 2025 | After the close | n/a | n/a | n/a | -2.1% | +1.2% | -7.6% |
| Feb 24, 2025 | After the close | n/a | n/a | n/a | -8.3% | -15.0% | -14.7% |
| Nov 6, 2024 | After the close | n/a | n/a | n/a | +8.5% | +2.0% | +8.0% |
| Aug 6, 2024 | After the close | n/a | n/a | n/a | +20.1% | +24.0% | +49.2% |
| May 7, 2024 | After the close | n/a | n/a | n/a | +3.1% | -4.3% | +9.5% |
| Feb 22, 2024 | After the close | n/a | n/a | n/a | -2.2% | -8.9% | -3.2% |
| Nov 7, 2023 | After the close | n/a | n/a | n/a | +3.9% | -3.6% | +5.2% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on VCYT and what the price did next.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for VCYT.
- 2/25/2026NEUTRALVeracyte (VCYT) Q4 2025 Earnings Call Transcript
Investors are keenly awaiting the transcript of Veracyte Inc.'s (VCYT) Q4 2025 earnings call, scheduled for February 25, 2026. While the announcement of such an event is standard for publicly traded companies, the current unavailability of the actual transcript content prevents any in-depth analysis of the financial data, future outlook, or strategic decisions discussed. The eventual release of these details will be crucial for understanding the company's performance and projections, potentially influencing market sentiment and investment decisions. Without this information, the market remains in a holding pattern, awaiting further clarity.